(¿Â¶óÀÎ)2020³â ´ëÇÑ°¨¿°ÇÐȸ¡¤´ëÇÑÇ×±Õ¿ä¹ýÇÐȸ Ãß°èÇмú´ëȸ : 2020-11-05±³À°ÀÏÀÚ : 2020-11-05
±³À°Àå¼Ò : ¿Â¶óÀÎ ±³À°
±³À°ÁÖÁ¦ :
(¿Â¶óÀÎ)2020³â ´ëÇÑ°¨¿°ÇÐȸ¡¤´ëÇÑÇ×±Õ¿ä¹ýÇÐȸ Ãß°èÇмú´ëȸ ÁÖÃÖ±â°ü : ´ëÇÑ°¨¿°ÇÐȸ
´ã´çÀÚ : Á¶À¯Áø
¿¬¶ôó : 02-2055-1441
À̸ÞÀÏ :
ksinfect@ksid.or.kr ±³À°Á¾·ù : ³»°ú, °áÇÙ°ú, Áø´Ü°Ë»çÀÇÇаú, º´¸®°úÀÇ»çÇÐ, ¿¹¹æÀÇÇÐ, ¹Ì»ý¹°ÇÐ, ±â»ýÃæÇÐ,
Âü¼®¿¹»óÀοø : 500¸í
Èñ¸ÁÆòÁ¡ : 6Á¡
Áö¿ª :
¼¿ïƯº°½Ã±³À°½Ã°£ : 7 ½Ã°£ 30ºÐ
¼¼ºÎ¼ö°·á : 120,000¿ø
ºñ°í Àü¹®ÀÇ,ÀϹÝ-100,000/Àü°øÀÇ-60,000/Çлý-40,000Àü¹®ÀÇ,ÀϹÝ-120,000/Àü°øÀÇ-80,000/Çлý-50,000
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 11¿ù 05ÀÏ ·Ôµ¥È£ÅÚ¿ùµå ·çºñ&Á¦À̵å·ë 09:10~09:30 Case 1 ±è¹ÎÀç(¿ï»êÀÇ´ë ¼¿ï¾Æ»êº´¿ø)
±³À°½Ã°£ 11¿ù 05ÀÏ ·Ôµ¥È£ÅÚ¿ùµå ·çºñ&Á¦À̵å·ë 09:30~09:50 Case 2 °íÀçÈÆ(¼º±Õ°üÀÇ´ë »ï¼º¼¿ïº´¿ø)
±³À°½Ã°£ 11¿ù 05ÀÏ ·Ôµ¥È£ÅÚ¿ùµå ·çºñ&Á¦À̵å·ë 09:50~10:10 Case 3 Á¤¼öÁø(¿¬¼¼ÀÇ´ë ¼¼ºê¶õ½ºº´¿ø)
ÈÞ½Ä 11¿ù 05ÀÏ ·Ôµ¥È£ÅÚ¿ùµå ·çºñ&Á¦À̵å·ë 10:10~10:20 Coffee break ()
±³À°½Ã°£ 11¿ù 05ÀÏ ·Ôµ¥È£ÅÚ¿ùµå ·çºñ&Á¦À̵å·ë 10:20~10:40 Pathogenesis and host immunity: lessions non-human primate model È«Á¤ÁÖ(»ý¸í°øÇבּ¸¿ø)
±³À°½Ã°£ 11¿ù 05ÀÏ ·Ôµ¥È£ÅÚ¿ùµå ·çºñ&Á¦À̵å·ë 10:40~11:00 Immunopathogenesis of SARS-CoV-2 ½ÅÀÇö(Ä«À̽ºÆ®)
±³À°½Ã°£ 11¿ù 05ÀÏ ·Ôµ¥È£ÅÚ¿ùµå ·çºñ&Á¦À̵å·ë 11:00~11:20 Human COVID-19 pathology autopsy ±èÈ¿Áø(¼¿ïÀÇ´ë)
Åä·Ð 11¿ù 05ÀÏ ·Ôµ¥È£ÅÚ¿ùµå ·çºñ&Á¦À̵å·ë 11:20~11:30 Q&A ()
ÈÞ½Ä 11¿ù 05ÀÏ ·Ôµ¥È£ÅÚ¿ùµå ·çºñ&Á¦À̵å·ë 11:30~11:40 Coffee break ()
±âŸ 11¿ù 05ÀÏ ·Ôµ¥È£ÅÚ¿ùµå ·çºñ&Á¦À̵å·ë 11:40~12:00 General assembly ()
±³À°½Ã°£ 11¿ù 05ÀÏ ·Ôµ¥È£ÅÚ¿ùµå ·çºñ&Á¦À̵å·ë 12:00~13:00 Áõ°¡ÇÏ´Â ¹éÀÏÇØ ¿¹¹æÀ» À§ÇÑ Tdap ¹é½Å Á¢Á¾ Àü·« ÀÌÈ¿Áø(°¡Å縯ÀÇ´ë)
½Ä»ç 11¿ù 05ÀÏ ·Ôµ¥È£ÅÚ¿ùµå ·çºñ&Á¦À̵å·ë 13:00~13:30 Lunch ()
±³À°½Ã°£ 11¿ù 05ÀÏ ·Ôµ¥È£ÅÚ¿ùµå ·çºñ&Á¦À̵å·ë 13:30~13:50 Strategy for evidence-based epidemiologic investigation ¹Ú¿µÁØ(Áúº´°ü¸®Ã»)
±³À°½Ã°£ 11¿ù 05ÀÏ ·Ôµ¥È£ÅÚ¿ùµå ·çºñ&Á¦À̵å·ë 13:50~14:10 School closure and opening during COVID-19 pandemic ±è¿¹Áø(¼º±Õ°üÀÇ´ë)
±³À°½Ã°£ 11¿ù 05ÀÏ ·Ôµ¥È£ÅÚ¿ùµå ·çºñ&Á¦À̵å·ë 14:10~14:30 Strategy for COVID-19 vaccination Á¤ÈñÁø(°í·ÁÀÇ´ë)
Åä·Ð 11¿ù 05ÀÏ ·Ôµ¥È£ÅÚ¿ùµå ·çºñ&Á¦À̵å·ë 14:30~14:50 Q&A ()
ÈÞ½Ä 11¿ù 05ÀÏ ·Ôµ¥È£ÅÚ¿ùµå ·çºñ&Á¦À̵å·ë 14:50~15:00 Coffee break ()
±³À°½Ã°£ 11¿ù 05ÀÏ ·Ôµ¥È£ÅÚ¿ùµå ·çºñ&Á¦À̵å·ë 15:00~16:00 Oral session I ¹é°æ¶õ(¼º±Õ°üÀÇ´ë)
ÈÞ½Ä 11¿ù 05ÀÏ ·Ôµ¥È£ÅÚ¿ùµå ·çºñ&Á¦À̵å·ë 16:00~16:10 Coffee break ()
±³À°½Ã°£ 11¿ù 05ÀÏ ·Ôµ¥È£ÅÚ¿ùµå ·çºñ&Á¦À̵å·ë 16:10~17:10 Oral session II ¿ìÈïÁ¤(ÇѸ²ÀÇ´ë)
ÈÞ½Ä 11¿ù 05ÀÏ ·Ôµ¥È£ÅÚ¿ùµå ·çºñ&Á¦À̵å·ë 17:10~17:20 Coffee break ()
±³À°½Ã°£ 11¿ù 05ÀÏ ·Ôµ¥È£ÅÚ¿ùµå ·çºñ&Á¦À̵å·ë 17:20~18:20 Maximizing patient survival while considering fragile patients: value of Cresemba in IMD À±¿µ°æ(°í·ÁÀÇ´ë)